Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study


To link to this article: https://doi.org/10.1080/00365521.2020.1790647

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 11 Jul 2020.

Article views: 221

Submit your article to this journal

View related articles

View Crossmark data
Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study

Jonathan R. White\textsuperscript{a,b,c}, Said Din\textsuperscript{c}, Richard J. M. Ingram\textsuperscript{d}, Stephen Foley\textsuperscript{d}, Mohammad Aftab Alam\textsuperscript{e}, Richard Robinson\textsuperscript{a}, Rodric Francis\textsuperscript{b}, Emily Tucker\textsuperscript{b}, Mustafa Jalal\textsuperscript{f}, David Elphick\textsuperscript{g}, Edmond Atallah\textsuperscript{a,g}, Anthony Norman\textsuperscript{g}, Muhammad Amin\textsuperscript{h}, Aamir Sajjad\textsuperscript{h}, Nicola Heggs\textsuperscript{i}, Simon Meadowcroft\textsuperscript{i} and Gordon W. Moran\textsuperscript{a,b}

\textsuperscript{a}NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK; \textsuperscript{b}Nottingham Digestive Diseases Centre, The University of Nottingham, Nottingham, UK; \textsuperscript{c}University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK; \textsuperscript{d}Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital, Sutton-In-Ashfield, UK; \textsuperscript{e}University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK; \textsuperscript{f}Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, UK; \textsuperscript{g}United Lincolnshire Hospitals NHS Trust, Lincoln County Hospital, Lincoln, UK; \textsuperscript{h}Kettering General Hospital NHS Foundation Trust, Kettering, UK; \textsuperscript{i}Takeda UK Ltd, High Wycombe, UK

\textbf{ABSTRACT}

\textbf{Purpose:} Clinical trials have demonstrated efficacy of vedolizumab in ulcerative colitis (UC) and Crohn’s disease (CD). Further real-world data is needed to inform clinical practice. The primary outcome was to assess corticosteroid-free and clinical remission after vedolizumab initiation. Secondary outcomes included effect on disease activity scores, biochemical markers, concomitant drug use, endoscopic remission, surgical intervention, hospital admissions and adverse events.

\textbf{Materials and methods:} A multi-centre retrospective observational study was conducted with patients initiated on vedolizumab across seven UK hospitals 1/11/14-30/11/16. Clinical disease activity was assessed using the partial Mayo Scores (pMS) and Harvey Bradshaw Index (HBI). Clinical remission was defined as HBI ≤4 or pMS <2 with a combined stool frequency and rectal bleeding sub score of ≤1. Clinical response was defined as ≥2-point decrease from baseline in pMS and ≥3-point decrease from baseline in HBI.

\textbf{Results:} One hundred ninety-two patients were included in the final analysis. 45% of UC and 10% of CD patients were anti-TNF naive. Over the observation period corticosteroid-free remission rates for UC and CD were 46% and 45%, while clinical remission rates were 52% and 44%, respectively. Time to corticosteroid free remission for UC and CD was 17.6 [IQR: 8.7–29.6] and 14.1 [IQR: 6.0–21.7] weeks, respectively. Time to clinical response for UC was 9.4 [IQR: 5.7–15.4] and CD was 9.5 [IQR: 6.1–18.2] weeks. There was a substantial decrease in the concomitant use of immunomodulators and a similar decrease in concomitant corticosteroid use over the study period.

\textbf{Conclusions:} Results in this predominately anti-TNF experienced population mirror other published real-world data, demonstrating good clinical effectiveness and a comparable safety profile.

\section*{Introduction}

Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic relapsing inflammatory diseases of the colon and gastrointestinal tract (GI). The estimated prevalence for UC is 250 per 100,000 and 150 per 100,000 for CD [1]. Due to the age of onset and disease duration, IBD medical management incurs a significant financial impact on world-wide healthcare systems [2]. The introduction of anti-tumour necrosis factor (anti-TNF) therapies with an established efficacy has greatly improved options for IBD patients, leading to an improvement in quality of life, reduction in hospitalisation and surgical procedures [3–7]. However, despite the advances in biologic therapy, the rates of primary non-response still remain significant at approximately 30%, and 23–46% of patients lose response over time, during the maintenance treatment [8–10]. New agents with alternative mechanisms of action have been developed.

Vedolizumab is a humanised monoclonal antibody that binds specifically to the $\alpha_4\beta_7$ integrin, a mediator of gastrointestinal inflammation [11,12]. Binding to $\alpha_4\beta_7$ on memory T-helper lymphocytes inhibits the adhesion to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on gut endothelial cells. The inhibition of this interaction prevents the transmigration of gut-homing memory T cells across the vascular endothelium and the subsequent...

\section*{CONTACT} Jonathan R. White, jonathan.white@nottingham.ac.uk, NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.

This article has been republished with minor changes. These changes do not impact the academic content of the article.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
The pivotal large-scale GEMINI clinical trials have demonstrated safety and efficacy of vedolizumab in both CD and UC with clinical remission rates of 39% and 42% maintained at 12 months [15,16]. Vedolizumab is effective in the treatment of anti-TNF naive and anti-TNF failure patients and benefits may continue long-term regardless of exposure status [17–19]. However, anti-TNF naive CD patients tend to respond better than those with previous exposure [18,20]. Vedolizumab was granted a Food and Drug Administration (FDA) and European Medicine Agency (EMA) licence for the treatment of moderate to severe UC and CD in 2014. Although clinical trial data is the gold standard on which to base recommendations, results obtained are not always generalisable in clinical practice. Clinical trial patient selection, efficacy outcomes, generalizability and reproducibility vary in comparison to clinical practice. Clinical trials also often lack data that is useful to clinicians and patients, such as time to first clinical remission and response and adverse events in real-world clinical practice. Robust data is required in the real-world setting to help inform practice and the appropriate place of vedolizumab in the IBD treatment algorithm. The recent LOVE-CD study aims to evaluate the efficacy of early versus late use of vedolizumab in CD [21]. While there are phase 3b studies demonstrating the efficacy of vedolizumab (for example, the VERSIFY study [22]), a limited number of real-world studies on vedolizumab have been published to date with only a few based in the UK [23–25].

We report the first real-world experience of vedolizumab in the treatment of IBD in the East Midlands. The primary objective was to describe rates of corticosteroid-free remission and clinical remission in patients with IBD after initiation on vedolizumab over the observation period. Secondary objectives were to describe the change in disease activity scores, median time to remission and response, concomitant drug use, endoscopic remission, surgical treatment, IBD-related hospital admissions and adverse events after initiation on vedolizumab.

### Materials and methods

#### Study population and design

A multicentre retrospective observational study was conducted with all patients initiated on vedolizumab across seven UK hospitals in the East Midlands. The participating centres included both large tertiary sites and smaller district general hospitals (Nottingham University Hospitals NHS Trust, University Hospitals of Derby and Burton NHS Foundation Trust, Sherwood Forest Hospitals NHS Foundation Trust, University Hospitals of Leicester NHS Trust, Chesterfield Royal Hospital NHS Foundation Trust, United Lincolnshire Hospitals NHS Trust and Kettering General Hospital NHS Foundation Trust). The study was designed and conducted according to the requirements of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) [26] and International Society for Pharmacoepidemiology (ISPE) guidance [27]. The study protocol was approved by the Health Research Authority (19/HRA/0008). This study was conducted as part of a regional service improvement project, therefore, NHS REC approval or written informed consent was not required. NHS approval for local conduct of the study and the sharing of anonymised patient data was sought and granted from the Research and Development (R&D) department in each centre. Patients initiated on vedolizumab between 1st November 2014 and 30th November 2016 were followed up until 31st March 2017 (Figure 1).

Vedolizumab was prescribed as recommended by the manufacturer, induction consisted of intravenous vedolizumab 300 mg at weeks 0, 2 and 6. Maintenance consisted of intravenous vedolizumab 300 mg every 8 weeks until treatment discontinuation or the last follow-up. The dosages of concomitant 5-ASAs, corticosteroids (prednisolone, hydrocortisone, budesonide, beclomethasone) and immunomodulators (azathioprine, mercaptopurine, cyclosporin, methotrexate) were recorded at each clinical visit.

![Figure 1. Observation period.](image)
Inclusion and exclusion criteria

Patients aged 18 years or older at initiation of vedolizumab, with a diagnosis of CD, UC or IBD of unclassified type (IBD-U) confirmed by endoscopic, radiological and histological criteria were included [28,29]. IBD-U patients were grouped with CD for the final analysis. Patients whose hospital medical records were unavailable for review or who were enrolled in an interventional clinical trial of an investigational medicinal product during the observation period or who did not receive vedolizumab or were recruited outside the data range for the study were excluded.

Data collection

Data was extracted and anonymised after extensive examination of medical records onto a pre-defined Microsoft Excel spreadsheet. The source data was a combination of clinical electronic and paper records: outpatient letters, prescriptions, day-case visits, laboratory and radiological investigations, endoscopy reports, emergency admissions, radiological and surgical intervention notes. Patient demographics prior to starting vedolizumab and clinical characteristics before and during each clinical visit for the whole treatment duration was recorded. Nottingham University Hospitals was the coordinating site which collated the data and raised any data queries with each participating hospital.

Outcome measures and definitions

Clinical disease activity was assessed at baseline, week 14, 30 and 52 using the Harvey-Bradshaw Index (HBI) and partial Mayo Score (pMS) [30,31]. Sixty-five percent of the disease activity scores were prospectively recorded and thirty-five percent of scores were calculated retrospectively from prospectively collected raw data from medical records. Raw data used for calculating scores was only used if the medical records matched the parameters and clinical evaluations used for the HBI and pMS scores. The primary outcome of this study was to investigate corticosteroid-free clinical remission defined as HBI ≤4 or pMS <2 with a combined stool frequency and rectal bleeding sub score of ≤1 and corticosteroid-free status after initiation of vedolizumab defined as absence of corticosteroid concomitant administration within two weeks either side of clinical scoring date. Secondary outcomes included: time to first clinical remission and clinical response (≥2-point decrease from baseline in pMS and ≥3-point decrease from baseline in HBI), endoscopic remission (absence of ulcers and inflammatory lesions assessed by endoscopy or small bowel magnetic resonance enterography) status at week 14 (±2 weeks), week 30 (±2 weeks) and 52 (±2 weeks) weeks. Other outcome measures included effect on disease activity scores, biochemical markers, concomitant drug use, hospital admissions (admission >24 h) and adverse effects. Patients who failed to show an improvement of symptoms and clinical signs with induction therapy were termed ‘primary non-responders’. Loss of response was defined as when patients lose response to vedolizumab therapy over time.

Statistical analysis

Parametric variables are presented as mean with standard deviations (SD) and non-parametric continuous variables as medians with interquartile ranges [IQR]. Categorical variables are described as frequency with percentages. Time-dependent variables are presented as Kaplan–Meier plots. Wilcoxon signed-rank test was used for analysis of continuous data. A p-value of <.05 was considered as statistically significant. SPSS 23 (IBM, Armonk, NY, USA) software was used for the statistical analysis.

Results

Patient demographics

A total of 206 patients were screened for the study. Fourteen patients were excluded due to not receiving a scheduled first dose of vedolizumab or the initiation date occurred outside the date range for this study. Medical records were available on all patients and none were enrolled into an interventional clinical trial. One hundred ninety-two patients (CD: 99, IBD-U: 6, UC: 87) were treated with vedolizumab. Patient demographics and disease extent are summarised in Table 1. One third of patients (29%) had a history of perianal involvement at baseline. Approximately 57% of patients with CD had at least one previous IBD related surgical procedure; 53% of patients had been hospitalised 12 months prior to starting vedolizumab, with a mean rate of hospitalisations during this time of 1.1 (IQR: 0.0–1.0).

Most patients had prior treatment with corticosteroids (96% and 98% for CD and UC, respectively) and immunomodulators (94% and 93% for CD and UC, respectively). About 90% of CD and 54% of UC patients had previous biologic therapy exposure; 45% and 46% of CD patients failed one or two anti-TNF agents, respectively. For UC, exposure was 41% and 13%, respectively for one or two anti-TNF agents. Median exposure to vedolizumab was 31.0 [IQR 21.3–51.1] weeks for CD and 38.4 [IQR 23.7–61.1] for UC (Table 2). The median study observation period for CD and UC was 36.3 weeks [IQR: 22.0–48.1, ≥10 weeks n = 103; ≥26 weeks n = 72; ≥48 weeks n = 30] and 40.4 weeks [IQR: 23.0–56.6, ≥10 weeks n = 85; ≥26 weeks n = 61; ≥48 weeks n = 34], respectively. Eleven patients with CD had vedolizumab infusions at week 10 (≥9 and <11). Four of these patients had only received two infusions of vedolizumab prior to their week 10 infusion.

Clinical remission and response

Following initiation on vedolizumab in CD, 27/60 (45%) of patients achieved corticosteroid-free remission with a median time of 14.1 weeks [IQR: 6.0–21.7]. For patients with UC, 39/87(46%) achieved corticosteroid-free remission with median time of 17.6 weeks [IQR: 8.7–29.6], Figure 2. Clinical remission
in CD was observed in 37/70 (44%) of patients (Table 3), with a median time of 10.1 weeks [IQR: 3.1–21.0]. For patients with UC, clinical remission was observed in 25/48 (52%) of patients with a median time of 15.1 weeks [IQR: 7.4–24.9]. For patients with CD, 53% achieved clinical response with a median time of 9.5 weeks [IQR: 6.1–18.2]. For patients with UC, 49% achieved clinical response with a median time of 9.4 weeks [IQR: 5.7–15.4]. Figures 3 and 4 summarise clinical remission for all IBD patients and according to prior anti-TNF exposure for UC patients.

### Disease activity

Clinical disease activity scores for UC reduced from baseline to: 14 weeks pMS 5 (IQR: 3–6) vs. 3 (IQR: 1–5) p = .025; 30 weeks pMS 5 (IQR: 3–6 vs. 2) (IQR: 1–5.5) p = .032; 52 weeks 5 (IQR: 3–6) vs. pMS 2 (IQR: 0–5) p = .27. For CD, disease activity scores decreased from baseline to: 14 weeks HBI 7 (IQR: 5–11) vs. 5 (IQR: 3–7.5) p = .059; 30 weeks HBI 7 (IQR: 5–11) vs. 6.5 (IQR: 2.5–8) p = .61; 52 weeks HBI 7 (IQR: 5–11) vs. 7 (IQR: 7–7) p = .78. Endoscopic remission (endoscopic examination or MRI) was achieved in 53% (25/47), 45% (15/33) and 50% (8/16) at 14, 30 and 52 weeks after initiation of vedolizumab, respectively. Endoscopically measured remission rates (based on SES-CD or endoscopic Mayo [UC] score) were 88% (21/24), 78% (14/18) and 50% (5/10) at week 14, 30 and 52 weeks, respectively. C-reactive protein for UC decreased from baseline by 52 weeks: 29.1 mg/L vs. 13.4 mg/L and decreased from baseline for CD at 52 weeks: 17.7 mg/L vs. 3.8 mg/L. Faecal calprotectin decreased by 14 weeks for UC: 1145 mg/g vs. 664 mg/g and CD 361 mg/g vs. 270 mg/g.

### Continuation of vedolizumab

At the end of the observation period, 63% of CD and 70% of UC patients remained on vedolizumab. A total of 65 patients discontinued vedolizumab therapy. The most common reasons for discontinuing vedolizumab in patients with CD/IBDU were primary non-response (28/36 [78%]) and intolerance (5/36 [14%]). The most common reasons in patients with UC were primary non-response (20/24 [83%]) and loss of response (3/24 [13%]).
Table 2. Treatment history.

<table>
<thead>
<tr>
<th>Treatment history</th>
<th>Overall (n = 192)</th>
<th>CD/IBDU (n = 105)</th>
<th>UC (n = 87)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vedolizumab indicationa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic or radiological evidence of active disease</td>
<td>39 (20%)</td>
<td>22 (21%)</td>
<td>17 (20%)</td>
</tr>
<tr>
<td>Corticosteroid dependency</td>
<td>21 (11%)</td>
<td>2 (2%)</td>
<td>19 (22%)</td>
</tr>
<tr>
<td>Intolerance to immunomodulators</td>
<td>21 (11%)</td>
<td>9 (9%)</td>
<td>12 (14%)</td>
</tr>
<tr>
<td>Intolerant to TNF inhibitors</td>
<td>23 (12%)</td>
<td>19 (18%)</td>
<td>4 (5%)</td>
</tr>
<tr>
<td>Primary non-responders to TNF inhibitors</td>
<td>67 (35%)</td>
<td>35 (33%)</td>
<td>32 (37%)</td>
</tr>
<tr>
<td>Loss of response to TNF</td>
<td>21 (11%)</td>
<td>18 (17%)</td>
<td>3 (3%)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>186 (97%)</td>
<td>101 (96%)</td>
<td>85 (98%)</td>
</tr>
<tr>
<td>N</td>
<td>6 (3%)</td>
<td>4 (4%)</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Immunomodulators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>180 (94%)</td>
<td>99 (94%)</td>
<td>81 (93%)</td>
</tr>
<tr>
<td>N</td>
<td>12 (6%)</td>
<td>6 (6%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>One immunomodulator</td>
<td>97 (51%)</td>
<td>55 (52%)</td>
<td>42 (48%)</td>
</tr>
<tr>
<td>Two immunomodulators</td>
<td>59 (31%)</td>
<td>29 (28%)</td>
<td>30 (34%)</td>
</tr>
<tr>
<td>Three immunomodulators</td>
<td>23 (12%)</td>
<td>14 (13%)</td>
<td>9 (10%)</td>
</tr>
<tr>
<td>Four immunomodulators</td>
<td>1 (1%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>150 (79%)</td>
<td>80 (76%)</td>
<td>70 (81%)</td>
</tr>
<tr>
<td>N</td>
<td>41 (21%)</td>
<td>25 (24%)</td>
<td>16 (19%)</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>19 (10%)</td>
<td>3 (3%)</td>
<td>16 (19%)</td>
</tr>
<tr>
<td>N</td>
<td>172 (90%)</td>
<td>102 (97%)</td>
<td>70 (81%)</td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>81 (42%)</td>
<td>44 (42%)</td>
<td>37 (43%)</td>
</tr>
<tr>
<td>N</td>
<td>110 (58%)</td>
<td>61 (58%)</td>
<td>49 (57%)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>38 (20%)</td>
<td>32 (30%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>N</td>
<td>153 (80%)</td>
<td>73 (70%)</td>
<td>80 (93%)</td>
</tr>
<tr>
<td>Anti-TNF status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naive</td>
<td>50 (26%)</td>
<td>10 (10%)</td>
<td>40 (46%)</td>
</tr>
<tr>
<td>Experienced</td>
<td>142 (74%)</td>
<td>95 (90%)</td>
<td>47 (54%)</td>
</tr>
<tr>
<td>One anti-TNF agent</td>
<td>83 (43%)</td>
<td>47 (45%)</td>
<td>36 (41%)</td>
</tr>
<tr>
<td>Two anti-TNF agents</td>
<td>59 (31%)</td>
<td>48 (46%)</td>
<td>11 (13%)</td>
</tr>
<tr>
<td>Median (weeks) exposure to vedolizumab</td>
<td>32.3 (22.0-54.0)</td>
<td>31.0 (21.3-51.1)</td>
<td>38.4 (23.7-61.1)</td>
</tr>
</tbody>
</table>

*Some patients had more than one indication for vedolizumab therapy.

Figure 2. Kaplan-Meier plot of time to corticosteroid-free remission.
**Concomitant medication**

For patients with CD, the number of patients with concomitant medication use decreased over the time of the study. At week 0, 27%, 26% and 23% of patients were co-prescribed corticosteroids, immunomodulators and aminosalicylates, respectively. By week 52, these proportions had decreased to 10%, 7% and 17%. A similar pattern was seen in patients with UC; at week 0, 48%, 41% and 67% of patients were taking corticosteroids, immunomodulators and aminosalicylates, respectively and by week 52 this had decreased to 15%, 18% and 41%. In patients who remained on concomitant therapy there was a reduction in the median dose from baseline to week 52. Budesonide median dose reduced from 9 mg (IQR: 6.0–9.0) at baseline to 2.5 mg (IQR: 2.0–3.0) at 52 weeks. Prednisolone median dose reduced from 30 mg (IQR: 27.5–40.0) at baseline to 20 mg (IQR: 10.0–25.0) at 52 weeks.

<table>
<thead>
<tr>
<th></th>
<th>CD</th>
<th>UC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroid free remission</td>
<td>45%</td>
<td>46%</td>
</tr>
<tr>
<td>Clinical remission</td>
<td>44%</td>
<td>52%</td>
</tr>
<tr>
<td>Clinical response</td>
<td>53%</td>
<td>49%</td>
</tr>
</tbody>
</table>

**Table 3.** Rates of remission and response to vedolizumab achieved during observation period.
Patients (53%) had at least one hospital admission in the 12 months preceding vedolizumab commencement. This reduced to 30% during the observation period. The mean rate of IBD-related hospital admissions prior to vedolizumab initiation per patient per year for CD and UC was 1.0 (IQR 0–1.0) and 0.9 (IQR 0–2.0), respectively. Following vedolizumab initiation, median rate of hospitalisation for CD and UC were 1.0 (IQR 0–1.0) and 1.0 (IQR 0–1.0), respectively. Twenty-six patients had IBD related surgery (12 patients with CD and 14 patients with UC) during the observation period after initiation of vedolizumab. Four of these patients had two surgical procedures. Overall, 12 adverse events were recorded in patients receiving vedolizumab during the study observation period. The most common was intolerance of vedolizumab \( (n = 5) \) (Table 4). About 9% of patients were admitted with infections, with respiratory tract infections being the most common. Three patients were diagnosed with a malignancy during the observation period. One patient was diagnosed with basal cell carcinoma and treated with surgery. They received 14 doses of vedolizumab which was later stopped due to loss of response. Another patient who received four doses of vedolizumab (which was later stopped due to non-response) was diagnosed with acute myeloid leukaemia and was started on chemotherapy. The final patient underwent a prostatectomy for prostate cancer. The vedolizumab was continued for more than 12 months by the end of the observation period.

**Discussion**

Following initiation on vedolizumab, clinical remission in patients with CD in this study was observed in 44% of patients with a median time of 10.1 weeks [IQR: 3.1–21.0]. For patients with UC, clinical remission was observed in 52% of patients with a median time of 15.1 weeks [IQR: 7.4–24.9]. In CD, 45% of patients achieved corticosteroid-free remission with a median time of 14.1 weeks [IQR: 6.0–21.7]. For patients with UC, 46% achieved corticosteroid-free remission with median time of 17.6 weeks [IQR: 8.7–29.6]. Despite positive results from the GEMINI licencing trials [15,16], real-world data is needed to describe the effectiveness of new therapeutic agents in routine clinical practice. The majority of patients in clinical practice do not fit the tight descriptors typical of pivotal licencing trials. Findings from this multi-centre cohort of patients with IBD demonstrate clinical effectiveness that is comparable to results from randomised controlled trials (RCTs) [15,16] and other studies [23,25,32–36]. Data from this study are generalizable to the rest of the UK due to the inclusion of both small district general hospitals and tertiary centres. Often real-world studies are hampered by incomplete datasets with drug persistence often being the primary outcome to determine long-term effectiveness. This study uses clinically measured disease scores as the tool of choice, making our findings more reflective of patient response to therapy.

Patient characteristics in this cohort, in particular median age and gender distribution are typical for IBD in the UK. Patients with CD were predominately anti-TNF experienced with a median disease duration of over 12 years. This reflects UK guidance from the National Institute of Health and Care Excellence (NICE) for vedolizumab which recommends use after an anti-TNF agent or when one is contraindicated. Whereas in UC, vedolizumab is recommended for use in biologic naïve patients when conventional therapy has failed [37,38]. In line with this UK guidance, the rates of corticosteroid and immunomodulatory drug use prior to initiation of vedolizumab were similar to previous real-world studies [32,33,39].

Drug persistence for vedolizumab was 70% and 63% respectively for UC and CD at the end of the study period, similar to previous studies. Ylisaukko-Oja et al., a Finnish cohort of 247 patients reported persistence rates of 66% and 75% for UC and CD, respectively at 6 months initiation [40]. Stallmach et al., a prospective study reported rates of 68% and 55% for UC and CD, respectively at week 30 [41]. Corticosteroid free remission, clinical remission and clinical responses were approximately 50% in this cohort. The GEMINI study reported clinical remission rates of 39% and 42% at 12 months for CD and UC, respectively [15,16] and the recent VARSITY study in UC patients reported clinical remission rates of 31.3% for vedolizumab patients at 12 months [42]. Real-world studies have reported clinical remission rates varying between 21% and 76%, measured at various time-points up to 54 weeks, for both CD and UC [43].

In this study, UC response rates were lower than those in CD. This finding is unique and had not been observed in previous real world and licencing trials. Forty-eight percent of UC patients were on concomitant corticosteroid therapy at the start of vedolizumab therapy as opposed to 27% in CD. Moreover, baseline disease activity in UC could be considered higher with a median pMS of 5 and a faecal calprotectin of 1145 \( \mu \)g/g as compared to a median HBI of 7 and a faecal calprotectin of 361 \( \mu \)g/g. These variables might indicate differential disease severity at baseline in these two diseases hence possibly explaining the observed efficacy in CD as compared to UC. Corticosteroid use in this study was consistent with previous studies which report rates between 29% and 84% [19,33,34,44,45]. Inflammatory burden of disease measured by CRP and FCP reduced following treatment initiation as expected.

The safety profile during follow-up was comparable to previous studies with rates of infections ranging between 1.7% and 12.6% [24,46,47]. However, the sample size and follow-up period were too small to detect significant safety signals.

Over the observation period approximately half of patients with available endoscopic images or small bowel
magnetic resonance enterography demonstrated endoscopic remission. These data suggest endoscopic remission with vedolizumab in both CD and UC though the number of patients undergoing these repeated objective investigations are relatively small (29 in CD and 18 in UC). The GEMINI 1 study reported mucosal healing rates in UC of 51.6% at 52 weeks [16]. Dulai et al., a real-world study reported mucosal healing cumulative rates in CD of 63% by 52 weeks of therapy [45]. Over time, a significant number of patients were able to de-escalate corticosteroid and immunomodulator use. Previous trials have demonstrated superiority of combination therapy (biologics with an immunomodulatory agent) over monotherapy [48,49]. Benefit with vedolizumab has not been extensively researched, however, post hoc analysis from GEMINI trials did not suggest additional benefit [50]. Allegretti et al., a multi-centre retrospective study of 136 patients conducted in the US described higher clinical responses for CD but not UC patients with combination therapy [51].

This was the first study to describe the reduction in concomitant medication with vedolizumab therapy in a large cohort of patients. Previous studies have described frequency but not the actual dosage change with vedolizumab. This study also describes ‘time-to’ data in a real-world setting, with results comparable to those reported in the GEMINI and VARSITY studies [15,16,42].

A major limiting factor for this study is the retrospective nature of the design with significant potential for missing data and short follow-up periods for some individuals. The variability of real-world clinical follow-up might have led to selection bias for clinical outcomes. The median time to analysis was defined by time seen in the clinic after induction therapy as reflects real-world practice. Although the majority of disease activity scores were recorded prospectively, some were derived retrospectively from medical records which may limit the accuracy of this data, an example of this is higher values of steroid-free remission seen than complete remission (baseline data was not always available to calculate complete response, whereas steroid-free remission is an absolute value at a specific timepoint). Endoscopic evaluation was also not uniformly available. When available it tended to be performed on individuals with a greater severity of disease. Mucosal healing observations should, therefore, be interpreted with caution as this was only assessed in a quarter of the cohort. Comparison with previous studies cannot accurately be made due to the differences in sample size, study region, clinical practice, patients and study outcome measures. Disease activity scores used to define remission and response vary amongst studies making interpretation of adverse event rates is challenging due to the retrospective design leaving the study open to recall bias in the collection of data alongside the lack of a control group. Moreover, another potential limitation was the lack of central reading for endoscopy reports or radiological imaging.

In this real-world vedolizumab cohort study, efficacy data for both UC and CD mirror previous RCTs and real-world data. A significant proportion of patients remained on vedolizumab by the end of the observation period. Our data demonstrated improved disease control, corticosteroid sparing and a decline in concomitant drug use with a comparable safety profile to phase III randomised controlled trials. In a cohort of complex and disease refractory IBD patients, vedolizumab is effective in a UK real-world setting.

Acknowledgments

Thomas Chu was involved in the conception and design of the study. The abstract of this article was presented as a part of conference proceeding at the European Crohn’s and Colitis Organisation annual meeting (Copenhagen, Denmark, March 2019) and the British Society of Gastroenterology annual meeting (Glasgow, UK, June 2019). Abstracts can be accessed through https://academic.oup.com/ecco-jcc/article-abstract/13/Supplement_1/5454/5300265?redirectedFrom=fulltext and https://gut.bmj.com/content/68/Suppl_2/A102.1. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Ethical approval

The Health Research Authority does not consider regional service improvement projects or post marketing surveillance research and therefore NHS REC approval was not required for this study.

Author contributions


Disclosure statement

N.H and S.M are employees of Takeda UK Ltd., and were both involved in the interpretation of the data and manuscript development. No other conflicts of interest to report for any authors.

Funding

This study was funded by Takeda UK Ltd. Medical writing and editorial support was provided by Mark Robinson, PhD, an employee of Takeda UK Ltd. J.R.W, E.A and G.W.M research is supported by the National Institute for Health Research (NIHR), through Nottingham Biomedical
References


